<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269735</url>
  </required_header>
  <id_info>
    <org_study_id>2640-001</org_study_id>
    <nct_id>NCT02269735</nct_id>
  </id_info>
  <brief_title>A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)</brief_title>
  <official_title>A Three-part Study Parts I, II and III: Rising Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Subjects (Part I) and Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Subjects With Type 1 Diabetes Mellitus (Part II and Part III).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Part I of this study is to evaluate the safety and tolerability of intravenous&#xD;
      (IV) doses of MK-2640 in healthy participants and to obtain preliminary plasma&#xD;
      pharmacokinetic profiles of MK-2640. The purpose of Parts II and III of this study is to&#xD;
      evaluate the safety and tolerability of IV doses of MK-2640 and regular human insulin (RHI),&#xD;
      and to evaluate the pharmacokinetic and pharmacodynamic profile of MK-2640 and RHI in&#xD;
      participants with type 1 diabetes mellitus (T1DM). Part II will be initiated only if Part I&#xD;
      general safety, tolerability and other observed data are supportive of progression to Part&#xD;
      II. Part III will be initiated only if Parts I and II general safety, tolerability and other&#xD;
      observed data are supportive of progression to Part III.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2014</start_date>
  <completion_date type="Actual">July 29, 2016</completion_date>
  <primary_completion_date type="Actual">July 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experienced an adverse event</measure>
    <time_frame>Up to 30 days following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: steady state plasma concentration (Css)</measure>
    <time_frame>Part I: final 30 minutes of each infusion rate; Parts II and III: final 30 minutes of each interval</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: area under the plasma concentration curve from time 0 to infinity (AUC [0 to infinity])</measure>
    <time_frame>Part I: 18 time points between predose and 600 minutes (min.); Part II: 19 time points between predose and 535 min.; Part III: 18 time points between predose and 415 min. following start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: clearance (CL)</measure>
    <time_frame>Part I: final 30 minutes of each infusion rate; Parts II and III: final 30 minutes of each interval</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: volume of distribution (Vd)</measure>
    <time_frame>Part I: final 30 minutes of each infusion rate; Parts II and III: final 30 minutes of each interval</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: plasma apparent terminal half-life</measure>
    <time_frame>Part II: following 9 hour infusion; Part III: following 7 hour infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic parameter: steady-state glucose infusion-rate (GIR) in Part II</measure>
    <time_frame>Part II: during the final 60 minutes of the infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued study drug due to an adverse event</measure>
    <time_frame>Part I: 1 day; Parts II and III: 9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibody (ADA) formation</measure>
    <time_frame>Up to 30 days following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel F)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2640 (Panel G)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: MK-2640 followed by RHI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: RHI followed by MK-2640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III: MK-2640 followed by RHI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III: RHI followed by MK-2640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2640</intervention_name>
    <description>MK-2640 intravenous infusion administered to participant in a fasted state</description>
    <arm_group_label>Part I: MK-2640 (Panel A)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel B)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel C)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel D)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel E)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel F)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel G)</arm_group_label>
    <arm_group_label>Part II: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part II: RHI followed by MK-2640</arm_group_label>
    <arm_group_label>Part III: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part III: RHI followed by MK-2640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Regular Human Insulin (RHI)</intervention_name>
    <description>RHI 100 units/mL intravenous infusion to maintain target glycemic level</description>
    <arm_group_label>Part II: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part II: RHI followed by MK-2640</arm_group_label>
    <arm_group_label>Part III: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part III: RHI followed by MK-2640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose</intervention_name>
    <description>Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level</description>
    <arm_group_label>Part I: MK-2640 (Panel A)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel B)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel C)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel D)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel E)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel F)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel G)</arm_group_label>
    <arm_group_label>Part II: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part II: RHI followed by MK-2640</arm_group_label>
    <arm_group_label>Part III: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part III: RHI followed by MK-2640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.</description>
    <arm_group_label>Part II: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part II: RHI followed by MK-2640</arm_group_label>
    <arm_group_label>Part III: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part III: RHI followed by MK-2640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue medication</intervention_name>
    <description>Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.</description>
    <arm_group_label>Part I: MK-2640 (Panel A)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel B)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel C)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel D)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel E)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel F)</arm_group_label>
    <arm_group_label>Part I: MK-2640 (Panel G)</arm_group_label>
    <arm_group_label>Part II: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part II: RHI followed by MK-2640</arm_group_label>
    <arm_group_label>Part III: MK-2640 followed by RHI</arm_group_label>
    <arm_group_label>Part III: RHI followed by MK-2640</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Part I):&#xD;
&#xD;
          -  healthy male or healthy female of non-child bearing potential&#xD;
&#xD;
          -  in good health&#xD;
&#xD;
          -  is a non-smoker and/or has not used nicotine or nicotine-containing products (e.g.,&#xD;
             nicotine patch) for at least approximately 3 months&#xD;
&#xD;
        Inclusion Criteria (Parts II and III):&#xD;
&#xD;
          -  male or female of non-child bearing potential&#xD;
&#xD;
          -  has T1DM for at least 12 months&#xD;
&#xD;
          -  on stable doses of insulin&#xD;
&#xD;
          -  in good health&#xD;
&#xD;
          -  is a nonsmoker and/or has not used nicotine or nicotine-containing products (e.g.,&#xD;
             nicotine patch) for at least approximately 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  is mentally or legally incapacitated, or has significant emotional problems at the&#xD;
             time of screening visit or expected during the conduct of the trial or has a history&#xD;
             of clinically significant psychiatric disorder of the last 5 years&#xD;
&#xD;
          -  has a history of clinically significant endocrine (except T1DM for Part II subjects),&#xD;
             gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal,&#xD;
             respiratory, genitourinary or major neurological (including stroke and chronic&#xD;
             seizures) abnormalities or diseases&#xD;
&#xD;
          -  is positive for hepatitis B surface antigen, hepatitis C antibodies or human&#xD;
             immunodeficiency virus (HIV)&#xD;
&#xD;
          -  has a history of cancer (malignancy), except adequately treated non-melanomatous skin&#xD;
             carcinoma or carcinoma in situ of the cervix&#xD;
&#xD;
          -  has a history of significant multiple and/or severe allergies, or has had an&#xD;
             anaphylactic reaction or significant intolerability to prescription or&#xD;
             non-prescription drugs or food, had major surgery, donated or lost 1 unit of blood&#xD;
             within 4 weeks prior to the screening visit&#xD;
&#xD;
          -  has participated in another investigational trial within 4 weeks prior to the&#xD;
             screening visit&#xD;
&#xD;
          -  is unable to refrain from or anticipates the use of any medication, including&#xD;
             prescription and non-prescription drugs or herbal remedies beginning approximately 2&#xD;
             weeks prior to administration of the initial dose of trial drug, throughout the trial,&#xD;
             until the posttrial visit&#xD;
&#xD;
          -  consumes greater than 3 glasses of alcoholic beverages daily&#xD;
&#xD;
          -  consumes greater than 6 servings of coffee, tea, cola, energy-drinks, or other&#xD;
             caffeinated beverages per day.&#xD;
&#xD;
          -  is currently a regular or recreational user of cannabis, any illicit drugs or has a&#xD;
             history of drug (including alcohol) abuse within approximately 3 months&#xD;
&#xD;
        Exclusion Criteria (Parts II and III):&#xD;
&#xD;
          -  has a history of diabetic ketoacidosis in the last 6 months.&#xD;
&#xD;
          -  has had one or more severe hypoglycemic episodes associated with hypoglycemic&#xD;
             seizures, comas or unconsciousness within 2 weeks prior to dosing&#xD;
&#xD;
          -  has used systemic (intravenous, oral, inhaled) glucocorticoids within 3 months of&#xD;
             screening or is anticipated to require treatment with systemic glucocorticoids during&#xD;
             study participation&#xD;
&#xD;
          -  has a history of hypersensitivity to pharmacologic insulins or to any of the inactive&#xD;
             ingredients in regular human insulin, or to any E. coli-derived drug product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Krug AW, Visser SAG, Tsai K, Kandala B, Fancourt C, Thornton B, Morrow L, Kaarsholm NC, Bernstein HS, Stoch SA, Crutchlow M, Kelley DE, Iwamoto M. Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive Properties. Clin Pharmacol Ther. 2019 Feb;105(2):417-425. doi: 10.1002/cpt.1215. Epub 2018 Sep 30.</citation>
    <PMID>30125349</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>MK-2640</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

